ZICCUM
Ziccum is developing new dry-powder versions of the worldโs most effective vaccines and biologic pharmaceuticals. These new, gently air-dried formulations can be transported easily and cost-effectively, with no costly cold storage or refrigeration required.
ZICCUM
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.ziccum.com
Total Employee:
1+
Status:
Active
Contact:
+46 709 61 55 99
Email Addresses:
[email protected]
Total Funding:
71.43 K EUR
Technology used in webpage:
HSTS Google Analytics 4 Person Schema Cloudflare JS CDN JS Gravatar Profiles ASP.NET IIS PostalAddress Schema IIS 10
Similar Organizations
Cobra Biologics
Cobra Biologics is providing a biologics and pharmaceuticals service.
Cristal Therapeutics
Cristal Therapeutics is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies.
Cyteir Therapeutics
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
KelSie Biotech
KelSie Biotech develops high bioavailability delivery methods to formulate and deliver sensitive active pharmaceutical ingredients.
Meshlin Composites
Meshlin trying to preserve the natural character of the materials and are to assure versatility and long life of our products.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
Terraplasma
Terraplasma offers solutions for the development of cold plasma products in areas where germs or unwanted odours lead to problems.
Current Employees Featured
Founder
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Ziccum
Official Site Inspections
http://www.ziccum.com Semrush global rank: 11.11 M Semrush visits lastest month: 170
- Host name: tama.oderland.com
- IP address: 46.16.236.16
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm

More informations about "Ziccum"
About - Ziccum
Apr 5, 2017 Board Fredrik Sjövall Chairman Born: 1980 Appointed: April 5, 2017. Qualifications: M.Sc. Automation Engineering, Masterโs Degree in Business Development. Independent of Ziccum and its senior management. โฆSee details»
Ziccum successfully dries Biologics by Mass Transfer
Jan 8, 2025 Ziccum's unique drying and formulation system LaminarPace is a new way of drying biologics. It eliminates heat stress, heat degradation and the need for elevated temperatures. Unlike other pharmaceutical drying systems, โฆSee details»
About us - Ziccum
Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. โฆSee details»
Ziccum - Crunchbase Company Profile & Funding
Ziccum focuses on drying mRNA/LNP, viral vectors using adenovirus, and subunit adjuvanted vaccines to improve their thermostability and administration routes. Novel Administration โฆSee details»
Ziccum Company Profile - Office Locations, Competitors ... - Craft
Ziccum is a company providing a technology that transforms vaccines, drugs, biologics, and chemicals into dry powders that can be transported and don't need temperature control. The โฆSee details»
Ziccum - Products, Competitors, Financials, Employees, โฆ
Ziccum AB Mon, Nov 04, 2024 11:00 CET The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Ann Gidner will present Ziccum to โฆSee details»
Ziccum Årsredovisning 2021
Den 1 december 2020 genomförde Ziccum ett listbyte till Nasdaq First North Growth Market. Bolagsinformation. Namn: Ziccum AB (publ) Organisationsnummer: 559107-9412. Juridisk โฆSee details»
Ziccum Årsredovisning 2021
Ziccum utvecklar ett processteg i en ny produktionsmetod för biologiska läkemedel och vacciner. Bolagets affärsmodell bygger på att ingå strategiska samarbeten och licensavtal för att โฆSee details»
Ziccum - VentureRadar
Ziccum is developing new dry-powder versions of the worldโs most effective vaccines and biologic pharmaceuticals. These new, gently air-dried formulations can be transported easily and cost โฆSee details»
Management team - Ziccum
May 9, 2022 Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active ingredient, LaminarPace® uniquely โฆSee details»
Ziccum - ZICCUM AB - reports-en.ziccum.com
Ziccum has two main goals for 2021: to make concrete plans to establish a demonstration facility for Fill and Finish based on the LaminarPace technology, and to continue the work around out โฆSee details»
Ziccum - ZICCUM AB - reports-en.ziccum.com
Ziccum's shares were listed on Spotlight Stock Markets on October 25, 2018. On December 1 2020, Ziccum moved to Nasdaq First North Growth Market. Market. Ziccum focuses on โฆSee details»
Ziccum - ZICCUM AB - reports.ziccum.com
Användningsområdena för teknologin är dock många fler, och potentialen väsentligt större vid tillämpning inom andra applikationsområden. Av den anledningen genomförde Inhalation โฆSee details»
Closing an intense year, building Ziccum to a new level (MFN)
Dec 23, 2024 The industry interest for Ziccumโs technology is substantial and increasing. It is of great value to ensure that Ziccum and LaminarPace® can help making new and better patient โฆSee details»
Investors - Ziccum
Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing drying stress to the active โฆSee details»
Ziccum - ZICCUM AB - reports-en.ziccum.com
Ziccum puts a lot of effort into developing the process of producing thermostable vaccines and adapting the technology for industrial production. This work is done with the aim of furthering โฆSee details»
Ziccum Updates - Ziccum
Ziccum heads West in 2024 to J P Morgan Week & Longwood Healthcare Leaders CEO Conference Ziccum heads West in 2024, Jan 6 โ 11, San Francisco. Book now to meet โฆSee details»
VD-Intervju på svenska: Ziccums senaste avtal och den ... - Placera
Jun 26, 2024 Om Ziccum. Ziccum utvecklar LaminarPace, en unik metod för torkning av biologiska läkemedel och vacciner i rumstemperatur. Metoden bygger på massöverföring โฆSee details»
Ziccum - ZICCUM AB - reports-en.ziccum.com
Ziccum Interim Report Q2 2021 Ziccum in short. Ziccum's patented technology LaminarPace air-dries liquid vaccine into a thermostable powder vaccine. Before it is administered, the vaccine โฆSee details»
News and Press Releases - Ziccum
Jan 8, 2025 Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. By reducing โฆSee details»